The company’s breast cancer vaccine, developed alongside the Cleveland Clinic, successfully concluded its Phase 1 clinical trial. Final data indicate that the vaccine met all major primary endpoints, proving safe and well-tolerated at the maximum dose. Notably, 74% of participants demonstrated a protocol-defined immune response to the treatment, which targets human α-lactalbumin—a protein expressed in certain breast cancers.
Anixa Biosciences Reports Progress in Breast and Ovarian Cancer Trials
Anixa Biosciences has unveiled promising clinical results for its two primary immunotherapy programs at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy symposium, marking a significant milestone in the company’s ongoing collaborations with the Cleveland Clinic and Moffitt Cancer Center.
Simultaneously, Anixa provided an update on its ovarian cancer CAR-T therapy, known as lira-cel. Currently in a Phase 1 trial with the Moffitt Cancer Center, the treatment targets the follicle-stimulating hormone receptor (FSHR). Early observations from the study are encouraging, with multiple patients surviving more than one year following treatment. The therapy utilizes chimeric endocrine receptor-T cell (CER-T) technology, which differentiates it from standard cell therapies by using the natural ligand of the FSHR receptor to bind to tumor cells.
Comments (0)
No comments yet. Be the first!